Qiagen launches QIAsymphony RGQ in Europe
This article was originally published in Clinica
Qiagen has launched the latest device in its QIAsymphony series, the QIAsymphony RGQ, in Europe. US launch is planned in early 2011, the firm told Clinica. The automated molecular diagnostic platform incorporates all workflow steps from sample to detection, and can test one to 72 samples per run. It can also process "an almost unlimited range of sample types", the Dutch company says. The new system can carry out PCR-based tests for disorders including HIV, hepatitis B and C, cytomegalovirus and Epstein-Barr virus. Qiagen is also planning to launch new tests "in the coming months", including ones for EGFR and KRAS gene mutations, and influenza. Older QIAsymphony devices include QIAsymphony AS and QIAsymphony SP.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.